Vitamin D in Dialysis Patients

Dialysis patients (CKD stage 5) have essentially zero renal 1α-hydroxylase activity. Cholecalciferol supplementation raises 25(OH)D but doesn't convert to active calcitriol. Managing CKD-MBD in dialysis requires active vitamin D analogues, calcimimetics, and calcium/phosphate balance under nephrology supervision.

The active analogues

Cholecalciferol still has a role

Dialysis patients often have very low 25(OH)D even with active analogue therapy. Standard cholecalciferol (1,000-2,000 IU/day or 50,000 IU/week) to raise 25(OH)D above 30 ng/mL is standard alongside active analogues. Supports non-renal functions of vitamin D (immune, muscle, bone matrix quality).

Calcimimetics

Cinacalcet (Sensipar) and etelcalcetide (Parsabiv) sensitise the parathyroid calcium-sensing receptor, suppressing PTH without raising serum calcium. Often combined with lower doses of active vitamin D to control PTH while minimising vascular calcification.

KDIGO targets in dialysis

What dialysis patients should NOT do

  1. Do not self-adjust vitamin D analogue doses.
  2. Do not stop calcimimetics without nephrology input.
  3. Do not use calcium-based supplements (e.g., Tums) as antacid without discussing with your kidney team — chronic accumulation contributes to vascular calcification.
  4. Do not take OTC magnesium without checking — dialysis alters magnesium handling.
  5. Sun exposure limits do not apply — even significant sun does not raise calcitriol without renal 1α-hydroxylase.
Sponsored
Not medical advice. Dialysis vitamin D management is complex and must be coordinated with your nephrology team. This overview is educational, not prescriptive.

Related tools & guides

Advertisement